USA flag logo/image

An Official Website of the United States Government

Development of a safe and effective chikungunya virus vaccine

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
88767
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
AI078652
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
GENPHAR, INC.
600 Seacoast Parkway MOUNT PLEASANT, SC 29464
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: Development of a safe and effective chikungunya virus vaccine
Agency: HHS
Contract: 1R43AI078652-01
Award Amount: $433,738.00
 

Abstract:

DESCRIPTION (provided by applicant): As recently as 2005-2006, a massive chikungunya (CHIK) outbreak occurred in the French Island of R union, infecting 35% of its 785,000 inhabitants and killing 237. Additionally, this disease is currently endemic in Indi a, in which 1.4 to 6.5 million cases are estimated to occur in 2006-2007. The name Chikungunya comes from Swahili for the bent walker, reflecting the physique of a person suffering from the severe joint pain associated with a chikungunya virus (CHIKV) in fection. Due to the rapid and long-term debilitating effects of this disease, the US government began to study possible mechanisms to counteract this potential bioterrorist threat as early as the 1960s. To date, no vaccine has been approved for public use to prevent the deleterious effects of this dangerous mosquito-borne arbovirus. While CHIKV has remained relatively unknown among non-endemic regions of the world, its potentially devastating effects should not be ignored considering: 1) its ability to debi litate affected individuals for weeks to months after the initial infection; and 2) its recent outbreak potential, particularly in areas where there is no prior immunity. Recent and ongoing epidemics of CHIK in several islands in the Indian Ocean, and in I ndia, have demonstrated how rapidly this arbovirus can spread through a na ve population and cause significant morbidity. The most effective approach to containing current and future outbreaks is to develop a safe and effective CHIK vaccine. Potential mark ets for this vaccine would include regions endemic for CHIKV, including multiple countries within Africa and Southeast Asia, and any potential travelers to these regions. Previously, our group has successfully developed effective recombinant vaccines again st various infectious disease agents based on a CAdVax vaccine platform. These vaccines successfully protected non-human primates (NHP) from challenges by all relevant subtypes of dengue, Ebola and Marburg viruses. If we consider that symptoms of CHIKV res emble those of dengue fever and either are misdiagnosed as dengue or coincide with dengue infections, another viable market would be individuals living in or traveling to areas endemic for one of both of these debilitating arboviral infections. For this re ason, we plan to develop a single-dose, multi-agent vaccine against both dengue and chikungunya viruses during our SBIR Phase II evaluations. PUBLIC HEALTH RELEVANCE: As seen last year in R union Island, chikungunya virus infection and outbreak is m ost severe when introduced into a region for which there is no prior immunity to the virus. Outbreaks of chikungunya fever can potentially incapacitate large populations of workers, leading to significant public health and economic distress. A safe and effective vaccine is the best means of preventing such naturally occurring outbreaks or potential outbreaks caused by biological attack.

Principal Investigator:

Business Contact:


jworara@genphar.com
Small Business Information at Submission:

GENPHAR, INC.
600 Seacoast Parkway MOUNT PLEASANT, SC 29464

EIN/Tax ID: 113405360
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No